Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol PFKFB2 contributors: mct - updated : 08-06-2021
HGNC name 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2
HGNC id 8873
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • an ATP binding site
  • two fructose-6-phosphate binding site
  • mono polymer homomer , dimer
    HOMOLOGY
    interspecies ortholog to rattus Pfkfb2
    ortholog to murine Pfkfb2
    Homologene
    FAMILY
  • phosphoglycerate mutase family, in the C-terminal section
  • CATEGORY enzyme
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,cytoplasm,cytosolic
    intracellular,nucleus,nucleoplasm
    basic FUNCTION
  • acting as a 6-phosphofructo-2-kinase
  • acting as a fructose 2,6-biphosphatase 2
  • involved in both the synthesis and degradation of fructose-2,6-bisphosphate, a regulatory molecule that controls glycolysis
  • regulates glycolysis and proliferation in pancreatic cancer cells
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism carbohydrate
    signaling
  • synthesis and degradation of fructose 2,6-bisphosphate
  • a component
    INTERACTION
    DNA
    RNA
    small molecule nucleotide, other,
  • ATP
  • fructose-6-phosphate
  • protein
  • MACC1 may affect hepatocellular carcinoma metabolism partly through expression and phophorylation of PFKFB2
  • cell & other
    REGULATION
    activated by phosphorylation, for the kinase activity
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    significantly higher in hepatocellular carcinoma than in the corresponding nontumor tissues
    constitutional     --over  
    in placentas from pregnancies with IUGR
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • biomarker for thyroid cancer exhibiting differences in the correlation coefficients between benign and malignant samples that indicate its discriminatory power
  • PFKFB2 promoter methylation analysis has potential applicability to better stratify WDTC patients according to the recurrence risk
  • Therapy target
    ANIMAL & CELL MODELS